{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T22:33:11Z","timestamp":1766788391653,"version":"3.37.3"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Aim<\/jats:title>\n                <jats:p>The aim of this study was to evaluate the clinical utility of SPECT\/CT (imaging of uptake in tumor lesions and additional findings) and the additional value of planar imaging in order to simplify clinical imaging protocols and decrease patients burden.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>One hundred consecutive patients with metastatic neuroendocrine tumor (NET) treated with PRRT were included. Post-therapy imaging was performed 24\u00a0h after each PRRT cycle by both whole-body planar imaging and abdominal- and thoracic SPECT\/CT. All images were evaluated for (1) the presence of new lesions, (2) discordant lesions between the two acquisitions (planar or SPECT), (3) location of lesions on SPECT (abdominal, thoracic, or both), and (4) additional findings on non-contrast enhanced CT imaging.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total 368 PRRT cycles including post-therapy imaging were performed in 100 patients. 45 patients had abdominal disease only, whilst in 55 patients the disease was observed on both abdominal and thoracic SPECT. 16 patients had known bone lesions that were visible only on planar imaging as these were out of range of the SPECT\/CT. During PRRT, one patient developed multiple new bone metastases after the second cycle of PRRT, which were visible on both planar and SPECT\/CT images. In 11 patients additional findings were found on CT images, the most common and relevant being bowel obstruction, pleural effusion, and ascites. Patients who developed ascites during PRRT appeared to do extremely poor; a post-hoc analysis showed that overall survival was 13.2\u00a0months in patients that showed ascites during PRRT at any moment and 37.9\u00a0months in patients without ascites (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>From a clinical point of view, thoracoabdominal SPECT\/CT imaging is the preferred method for post-PRRT imaging; planar imaging had no added value over SPECT\/CT in this cohort. In patients with abdominal disease only on baseline imaging, SPECT\/CT of the abdomen only might be sufficient for imaging during the PRRT course. All accompanying CT images should be reviewed for additional findings, especially ascites, which is suggested to be a poor prognostic factor in patients receiving PRRT.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40644-022-00467-1","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T10:04:26Z","timestamp":1655460266000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Post-PRRT scans: which scans to make and what to look for"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4910-3794","authenticated-orcid":false,"given":"Else A.","family":"Aalbersberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1967-8148","authenticated-orcid":false,"given":"Daphne M. V.","family":"de Vries\u2013Huizing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margot E. T.","family":"Tesselaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel P. M.","family":"Stokkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle W. J.","family":"Versleijen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"issue":"991","key":"467_CR1","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.neo.2017.09.002","volume":"19","author":"B Oronsky","year":"2017","unstructured":"Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas. Neoplasia. 2017;19(991):1002. https:\/\/doi.org\/10.1016\/j.neo.2017.09.002.","journal-title":"Neoplasia"},{"key":"467_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017;376:125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1607427.","journal-title":"N Engl J Med"},{"key":"467_CR3","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","volume":"40","author":"JJ Zaknun","year":"2013","unstructured":"Zaknun JJ, Bodei L, Mueller-Brand J, Pavel ME, Baum RP, H\u00f6rsch D, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800\u201316.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"467_CR4","doi-asserted-by":"publisher","first-page":"e0260073","DOI":"10.1371\/journal.pone.0260073","volume":"16","author":"DMV de Vries-Huizing","year":"2021","unstructured":"de Vries-Huizing DMV, Versleijen MWJ, Sinaasappel M, Walraven I, Geluk-Jonker MM, Tesselaar MET, et al. Haematotoxicity during peptide receptor radionuclide therapy: baseline parameters differences and effect on patient\u2019s therapy course. PLoS One. 2021;16:e0260073.","journal-title":"PLoS One"},{"key":"467_CR5","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/acm2.12991","volume":"21","author":"DMV Huizing","year":"2020","unstructured":"Huizing DMV, Sinaasappel M, Dekker MC, Stokkel MPM, de Wit-van der Veen BJ. 177Lutetium SPECT\/CT: Evaluation of collimator, photopeak and scatter correction. J Appl Clin Med Phys. 2020;21:272\u20137.","journal-title":"J Appl Clin Med Phys."},{"key":"467_CR6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13550-018-0443-z","volume":"8","author":"DMV Huizing","year":"2018","unstructured":"Huizing DMV, de Wit-van der Veen BJ, Verheij M, Stokkel MPM. Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review. EJNMMI Res. 2018;8:89.","journal-title":"EJNMMI Res"},{"key":"467_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2155-9619.1000395","volume":"10","author":"S Mahajan","year":"2019","unstructured":"Mahajan S, O\u2019Donoghue J, Weber W, Bodei L. Integrating early rapid post-peptide receptor radionuclide therapy quality assurance scan into the outpatient setting. J Nucl Med Radiat Ther. 2019;10:1\u201314.","journal-title":"J Nucl Med Radiat Ther"},{"key":"467_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/jso.25453","volume":"120","author":"C Hodge","year":"2019","unstructured":"Hodge C, Badgwell BD. Palliation of malignant ascites. J Surg Oncol. 2019;120:67\u201373. https:\/\/doi.org\/10.1002\/jso.25453.","journal-title":"J Surg Oncol."},{"key":"467_CR9","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s12149-017-1163-6","volume":"31","author":"J Kunikowska","year":"2017","unstructured":"Kunikowska J, Pawlak D, B\u0105k MI, Kos-Kud\u0142a B, Miko\u0142ajczak R, Kr\u00f3licki L. Long-term results and tolerability of tandem peptide receptor radionuclide therapy with90Y\/177Lu-DOTATATE in neuroendocrine tumors with respect to the primary location: a 10-year study. Ann Nucl Med Springer Japan. 2017;31:347\u201356.","journal-title":"Ann Nucl Med Springer Japan"},{"key":"467_CR10","unstructured":"Summary of product characteristics. Lutathera. Accessed via https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lutathera-epar-product-information_en.pdf on 07\u201304\u20132022."},{"key":"467_CR11","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1007\/s00259-022-05727-7","volume":"49","author":"K Sj\u00f6greenGleisner","year":"2022","unstructured":"Sj\u00f6greenGleisner K, Chouin N, MinguezGabina P, et al. EANM dosimetry committee recomendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. Eur J Nucl Med Mol Imaging. 2022;49:1778\u2013809.","journal-title":"Eur J Nucl Med Mol Imaging."}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-022-00467-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-022-00467-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-022-00467-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T10:17:36Z","timestamp":1655461056000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerimagingjournal.biomedcentral.com\/articles\/10.1186\/s40644-022-00467-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["467"],"URL":"https:\/\/doi.org\/10.1186\/s40644-022-00467-1","relation":{},"ISSN":["1470-7330"],"issn-type":[{"type":"electronic","value":"1470-7330"}],"subject":[],"published":{"date-parts":[[2022,6,17]]},"assertion":[{"value":"7 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Institutional Review Board (IRBd20-078).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29"}}